{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:40:29Z","timestamp":1779928829168,"version":"3.53.1"},"reference-count":8,"publisher":"Japanese Circulation Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2025,5,23]]},"DOI":"10.1253\/circj.cj-24-0898","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T22:15:42Z","timestamp":1744928142000},"page":"784-792","source":"Crossref","is-referenced-by-count":5,"title":["Post-Marketing Surveillance of the Safety of Landiolol in Patients With Recurrent Hemodynamically Unstable Ventricular Tachyarrhythmias"],"prefix":"10.1253","volume":"89","author":[{"given":"Tsuyoshi","family":"Shiga","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, The Jikei University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Shiozaki","sequence":"additional","affiliation":[{"name":"Section 2, PMS Office, Pharmacovigilance Division, Ono Pharmaceutical Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Section 3, Strategy Office, Safety Management Department, Pharmacovigilance Division, Ono Pharmaceutical Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Medical Information Section, Medical Resource Division, Department of Medical Affairs, Ono Pharmaceutical Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Fukui","sequence":"additional","affiliation":[{"name":"Section 1, Primary Medical Affairs Division, Department of Medical Affairs, Ono Pharmaceutical Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Bay\u00e9s de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: Mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. <i>Am Heart J<\/i> 1989; 117: 151\u2013159, doi:10.1016\/0002-8703(89)90670-4.","DOI":"10.1016\/0002-8703(89)90670-4"},{"key":"2","unstructured":"2. Japan Circulation Society, Japanese Heart Rhythm Society. JCS\/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias, including focused update for arrhythmia treatment [in Japanese]. 2024. https:\/\/www.j-circ.or.jp\/cms\/wp-content\/uploads\/2020\/01\/JCS2020_Ono.pdf (accessed May 23, 2024)."},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Ono K, Iwasaki YK, Akao M, Ikeda T, Ishii K, Inden Y, et al. JCS\/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias. <i>Circ J<\/i> 2022; 86: 1790\u20131924, doi:10.1253\/circj.CJ-20-1212.","DOI":"10.1253\/circj.CJ-20-1212"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Takase B, Ikeda T, Shimizu W, Abe H, Aiba T, Chinushi M, et al. JCS\/JHRS 2022 guideline on diagnosis and risk assessment of arrhythmia. <i>Circ J<\/i> 2024; 88: 1509\u20131595, doi:10.1253\/circj.CJ-22-0827.","DOI":"10.1253\/circj.CJ-22-0827"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Hanada K, Kinjo T, Yokoyama H, Tsushima M, Senoo M, Ichikawa H, et al. Incidence, predictors, and outcome associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. <i>Circ J<\/i> 2024; 88: 1254\u20131264, doi:10.1253\/circj.CJ-23-0023.","DOI":"10.1253\/circj.CJ-23-0023"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Ikeda T, Shiga T, Shimizu W, Kinugawa K, Sakamoto A, Nagai R, et al. Efficacy and safety of the ultra-short-acting \u03b2<sub>1<\/sub>-selective blocker landiolol in patients with recurrent hemodynamically unstable ventricular tachyarrhymias: Outcomes of J-Land II study. <i>Circ J<\/i> 2019; 83: 1456\u20131462, doi:10.1253\/circj.CJ-18-1361.","DOI":"10.1253\/circj.CJ-18-1361"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Matsuishi Y, Mathis BJ, Shimojo N, Kawano S, Inoue Y. Evaluating the therapeutic efficacy and safety of landiolol hydrochloride for management of arrhythmia in critical settings: Review of the literature. <i>Vasc Health Risk Manag<\/i> 2020; 16: 111\u2013123, doi:10.2147\/vhrm.S210561.","DOI":"10.2147\/VHRM.S210561"},{"key":"8","unstructured":"8. Ono Pharmaceutical. ONOACT<sup>\u00ae<\/sup> (landiolol) for i.v. infusion. Interview form, July 2023 (revision 14) [in Japanese]. https:\/\/www.ononavi1717.jp\/system\/files\/2023-07\/OA_IF_5.pdf (accessed May 23, 2024)."}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/89\/6\/89_CJ-24-0898\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T03:46:50Z","timestamp":1748058410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/89\/6\/89_CJ-24-0898\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-24-0898","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"article-number":"CJ-24-0898"}}